drugset / Trial / NCT03329989

Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

NCT03329989

Phase 2 Completed 158 enrolled Endo USA Inc., a Keenova Therapeutics Company
NaSingle-groupOpen-labelTreatment

Summary

An open-label study of safety and effectiveness of EN3835 in the treatment of cellulite in adult women.

Timeline

Start
2017-11-17
Primary completion
2018-09-05
Completion
2018-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.84 mg Other